Apyx Medical Corp 8-K/A, filed Mar 21, 2022
Apyx Medical Corp (APYX)
8-K/A
2022-03-21
For: 2019-08-01
View Original
Added on
April 06, 2026
About this 8-K/A
Apyx Medical Corp filed this 8-K/A on March 21, 2022, reporting on events of August 1, 2019.
Items reported
- Item 5.02: Director or officer change, or executive pay
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K/A
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (date of earliest event reported)
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation or organization) | (Commission File Number) | (I.R.S. Employer Identification No.) | |||||||||
(Address of principal executive offices, zip code)
(727 ) 384-2323
(Issuer's telephone number)
_____________________________________________________________
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
o
EXPLANATORY NOTE
Apyx Medical Corporation (the “Company”) is filing this Amendment No. 1 on Form 8-K (this “Amended Filing”) to amend: (i) its Current Report on Form 8-K filed with the Securities and Exchange Commission on August 7, 2019 (“Original Filing 1”); and (ii) its Current Report on Form 8-K filed with the Securities and Exchange Commission on August 30, 2021 (“Original Filing 2” and together with Original Filing 1, collectively, the “Original Filings”), solely to provide information required by Item 5.02 (d)(3), that was previously undetermined as of the respective filing dates of the Original Filings.
| Item 5.02 | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. | ||||
As previously reported on Original Filing 1, the Company’s Board of Directors (the “Board”) appointed Minnie Baylor-Henry to serve as a director of the Company and as Chair of the Regulatory and Compliance Committee. At the time of this appointment, the Board had not made any determinations regarding additional committee assignments for Ms. Baylor-Henry. On March 15, 2022, the Board appointed Ms. Baylor-Henry as a member of the Nominating and Governance Committee, effective on that date.
Similarly, as previously reported on Original Filing 2, the Board appointed Wendy Levine to serve as a director of the Company. At the time of this appointment, the Board had not made a determination regarding any committee assignments for Ms. Levine. On March 15, 2022, the Board appointed Ms. Levine as a member of the Compensation Committee, effective on that date.
This Amended Filing is filed as an amendment to each of the above-mentioned Original Filings and in accordance with instruction no. 2 of the Instructions to Item. 5.02.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: March 21, 2022 | Apyx Medical Corporation | ||||||||||
| By: | /s/ Tara Semb | ||||||||||
| Tara Semb | |||||||||||
| Chief Financial Officer, Secretary and Treasurer | |||||||||||